Advertisement

Patch Testing in Adverse Drug Reactions

  • Margarida GonçaloEmail author
  • Derk P. Bruynzeel
Living reference work entry
  • 6 Downloads

Abstract

Patch testing primarily indicated for the study of T-cell-mediated allergic contact dermatitis also has an important place in the diagnosis of T-cell-mediated (non-immediate) drug eruptions, which include maculopapular exanthema, DRESS, SJS/TEN, AGEP, SDRIFE, fixed drug eruption, and drug photoallergy.

When facing a possible drug eruption, it is of outmost importance to characterize the clinical pattern and obtain a complete history of drug exposure and its chronologic relation with the onset or aggravation of cutaneous lesions. After resolution of the eruption, patch testing can be used as a safe form of cutaneous provocation to confirm the culprit drug and cross-reactive chemicals. A positive test performed according to the recommendations is highly specific and reproducible, even after long intervals. Patch testing can be performed as a first step before an oral challenge, which has more risks and is contraindicated in severe drug eruptions.

It is advised to patch test all possible culprits and related drugs, as patch testing can also be used to study concomitant sensitizations and cross-reactions, which can vary with the drug, way of exposure and pattern of the drug reaction. A positive cross-reactive reaction can advise future drug avoidance, whereas a negative reaction can be an indication for using the drug in an oral challenge to ascertain its safety.

Methodology and interpretation of patch testing in drug eruptions is similar to allergic contact dermatitis. As there are few commercialized patch test substances, in most cases drugs have to be prepared in-house, whenever possible in a final dilution of the active principle at 10% pet. Application on the back and occlusion for 48 h is recommended except in fixed drug eruptions where duplicate tests are needed, one of them applied for 24 h on a residual lesion.

Patch test reactivity with drugs depends mainly on the culprit drugs and on the clinical pattern of the eruption. Patch testing is positive mostly in maculopapular exanthemas, DRESS, and fixed drug eruptions and less often in SJS/TEN. For drugs like abacavir, carbamazepine, pristinamycin, and tetrazepam, patch tests are almost always positive, and reactivity to aminopenicillins and other antibiotics, diltiazem, and radiocontrast media and some NSAIDs is usually above 20% or higher in selected cases with high clinical imputability. Allopurinol and sulfasalazine cannot be identified by patch testing, and sensitivity of patch tests for several drugs is not known.

Therefore, a negative patch test cannot exclude a possible culprit, but a positive patch test is almost always relevant, can confirm drug imputability, evaluate cross-reactions, and study the mechanisms involved in the reaction.

Keywords

Patch testing Non-immediate drug eruptions Drug patch tests Cross-reactions Histopathology DRESS TEN AGEP Maculopapular exanthema Fixed drug eruption 

References

  1. 1.
    Borch JE, Andersen KE, Bindslev-Jensen C (2006) The prevalence of acute cutaneous drug reactions in a Scandinavian university hospital. Acta Derm Venereol 86(6):518–522PubMedCrossRefPubMedCentralGoogle Scholar
  2. 2.
    Bigby M (2001) Rates of cutaneous reactions to drugs. Arch Dermatol 137:765–770PubMedPubMedCentralGoogle Scholar
  3. 3.
    Phillips EJ, Bigliardi P, Bircher AJ, Broyles A (2018) Controversies in drug allergy: testing for delayed reactions. J Allergy Clin Immunol 143(1):66–73PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Gonçalo M, Bruynzeel D (2012) Mechanisms in cutaneous drug hypersensitivity reactions. In: Wilhem K, Zhai H, Maibach H (eds) Dermatotoxicology, 2nd edn. CRC Press, Boca Raton, pp 78–92Google Scholar
  5. 5.
    Santiago F, Gonçalo M, Reis J, Figueiredo A (2011) Adverse cutaneous reactions to epidermal growth factor receptor inhibitors: a study of 14 patients. An Bras Dermatol 86(3):483–490PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Friedmann P (2003) Mechanisms in cutaneous drug hypersensitivity. Clin Exp Allergy 33:861–872PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Pichler WJ (2019) Immune pathomechanism and classification of drug hypersensitivity. Allergy 74(8):1457–1471Google Scholar
  8. 8.
    Peter JG, Lehloenya R, Dlamini S, Risma K, White KD, Konvinse KC et al (2017) Severe delayed cutaneous and systemic reactions to drugs: a global perspective on the science and art of current practice. J Allergy Clin Immunol Pr 5(3):547–563CrossRefGoogle Scholar
  9. 9.
    Laurinaviciene R, Sandholdt L, Bygum A (2017) Drug-induced cutaneous lupus erythematosus: 88 new cases. Eur J Dermatol 27(1):28–33PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Pinto Gouveia M, Gameiro A, Coutinho I, Pereira N, Cardoso JC, Gonçalo M (2016) Overlap between maculopapular exanthema and drug reaction with eosinophilia and systemic symptoms among cutaneous adverse drug reactions in a dermatology ward. Br J Dermatol 175(5):1274–1283PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Peermohamed S, Haber R (2011) Acute generalized exanthematous pustulosis simulating toxic epidermal necrolysis: a case report and review of the literature. Arch Dermatol 147:697–701PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Wang C, Dao R, Chung W (2016) Immunopathogenesis and risk factors for allopurinol severe cutaneous adverse reactions. Curr Opin Allergy Clin Immunol 16(4):339–345PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Moore N, Biour M, Paux G, Loupi E, Bégaud B, Boismare F et al (1985) Adverse drug reaction monitoring: doing it the French way. Lancet 326:1056–1058CrossRefGoogle Scholar
  14. 14.
    Porebski G (2017) In vitro assays in severe cutaneous adverse drug reactions: are they still research tools or diagnostic tests already? Int J Molec Sci 18(8):1–17CrossRefGoogle Scholar
  15. 15.
    Hjortlund J, Mortz CG, Skov PS, Eller E, Poulsen JM, Borch JE et al (2012) One-week oral challenge with penicillin in diagnosis of penicillin allergy. Acta Derm Venereol 92(3):307–312PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Hjortlund J, Mortz CG, Skov PS, Bindslev-Jensen C (2013) Diagnosis of penicillin allergy revisited: the value of case history, skin testing, specific IgE and prolonged challenge. Allergy 68(8):1057–1064PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Barbaud A, Gonçalo M, Bircher A, Bruynzeel D (2001) Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermatitis 45:321–328PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Johansen J, Aalto-Korte K, Agner T, Andersen K, Bircher A, Bruze M et al (2015) European Society of Contact Dermatitis guideline for diagnostic patch testing – recommendations on best practice. Contact Dermatitis 73(4):195–221CrossRefGoogle Scholar
  19. 19.
    Redwood AJ, Pavlos RK, White KD, Phillips EJ (2018) Human leukocyte antigens: key regulators of T-cell mediated drug hypersensitivity. HLA 91(1):3–16PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Gonçalo M (2019) Clinical features of contact dermatitis. In: Brockow K, Mortz C (Eds) Global Atlas of skin allergy. EAACI, pp 116–118Google Scholar
  21. 21.
    Gonçalo M, Cardoso J, Gouveia M, Coutinho I, Gameiro A, Brites M et al (2016) Histopathology of the exanthema in DRESS is not specific but may indicate severity of systemic involvement. Am J Dermatopathol 38(6):423–433PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Pinheiro V, Pestana C, Pinho A, Antunes I, Gonçalo M (2018) Occupational allergic contact dermatitis caused by antibiotics in healthcare workers – relationship with non-immediate drug eruptions. Contact Dermatitis 78(4):281–286PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Khalid A, Ghaffar S (2019) Two cases of occupational allergic contact dermatitis caused by abacavir. Contact Dermatitis 80(3):187–188PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Whitaker P (2016) Occupational allergy to pharmaceutical products. Curr Opin Allergy Clin Immunol 16(2):101–106PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Kerr A, Muller F, Ferguson J, Dawe R (2008) Occupational carprofen photoallergic contact dermatitis. Br J Dermatol 159:1303–1308PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    DeKoven J, Yu A (2015) Occupational airborne contact dermatitis from proton pump inhibitors. Dermatitis 26(6):287–290PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Hausermann P, Harr T, Bircher A (2004) Baboon syndrome resulting from systemic drugs: is there strife between SDRIFE and allergic contact dermatitis syndrome? Contact Dermatitis 51:297–310PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Van Den Hoed E, Coenraads P-J, Schuttelaar ML (2019) Morphine-induced cutaneous adverse drug reaction following occupational diacetylmorphine contact dermatitis: a case report. Contact Dermatitis 81(4):313–315PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Pinho A, Marta A, Coutinho I, Gonçalo M (2017) Long-term reproducibility of positive patch test reactions in patients with non-immediate cutaneous adverse drug reactions to antibiotics. Contact Dermatitis 76(4):204–209PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Braun V, Darrigrade A-S, Milpied B (2018) Positive patch test reaction to carbamazepine after a very long delay. Contact Dermatitis 79(4):240–241PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Serra D, Gonçalo M, Mariano A, Figueiredo A (2011) Pustular psoriasis and drug-induced pustulosis. Giorn Ital Dermatol Venerol 146(2):155–158Google Scholar
  32. 32.
    Serra D, Ramos L, Brinca A, Gonçalo M (2012) Acute generalized exanthematous pustulosis associated with acyclovir, confirmed by patch testing. Dermatitis 23(2):99–100PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Gómez MTB, García CM, Yebra CM, Cobo MIZ, Álvarez MEC, Estella JS (2018) First case report of acute generalized exanthematous pustulosis (AGEP) caused by gadolinium confirmed by patch testing. Contact Dermatitis 78(2):166–168CrossRefGoogle Scholar
  34. 34.
    Gonçalo M, Santiago F, Julião M, Tellechea O (2010) Postive patch test in toxic epidermal necrolysis with clinical and histopathological aspect typical of TEN. Contact Dermatitis 63(S1):22–23Google Scholar
  35. 35.
    Gonçalo M, Cardoso J, Coutinho I, Gameiro A, Tellechea O (2014) Histopathology of patch tests depends on the pattern of CADR, not on the culprit drug. Contact Dermatitis 70(S1):36–37Google Scholar
  36. 36.
    Gonçalo M, Serra D, Cabral A, Reis J, Tellechea O (2011) Histopathology of positive skin tests in different drug eruptions. J Invest Dermatol S33:131Google Scholar
  37. 37.
    Yawalkar N, Hari Y, Frutig K, Egli F, Wendland T, Braathen L et al (2000) T cells isolated from positive epicutaneous test reactions to amoxicillin and ceftriaxone are drug specific and cytotoxic. J Invest Dermatol 115(4):647–652PubMedCrossRefGoogle Scholar
  38. 38.
    Lachapelle J-M (2011) Historical aspects. In: Johansen J, Frosch P, Lepoittevin J (eds) Contact dermatitis, 5th edn. Springer, Berlin/Heidelberg, pp 1–9Google Scholar
  39. 39.
    Bruynzeel D, Von Blomberg-van der Flier M, Scheper R, Van Ketel W, De Haan P (1985) Penicillin allergy and the relevance of epicutaneous tests. Dermatologica 171:429–434PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Camarasa J (1985) Patch test diagnosis of exfoliative dermatitis due to carbamazepine. Contact Dermatitis 12:49PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Silva R, Machado A, Brandão M, Gonçalo S (1986) Patch test diagnosis in carbamazepine erythroderma. Contact Dermatitis 15(4):254–255PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Barbaud A (2002) Tests cutanés dans l’investigation des toxidermies: de la physiopathologie aux résultats des investigations. Therapie 57:258–262PubMedPubMedCentralGoogle Scholar
  43. 43.
    Lammintausta K, KorteKangas-Savolainen O (2005) The usefulness of skin tests to prove drug hypersensitivity. Br J Dermatol 152:968–974PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Santiago F, Gonçalo M, Vieira R, Coelho S, Figueiredo A (2010 Jan) Epicutaneous patch testing in drug hypersensitivity syndrome (DRESS). Contact Dermatitis 62(1):47–53PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Gonçalo M (2019) Usefulness of cutaneous provocation tests to study drugs responsible for cutaneous adverse drug reactions. Curr Treat Options Allergy 6(1):112–124CrossRefGoogle Scholar
  46. 46.
    Andrade P, Brinca A, Gonçalo M (2011 Oct) Patch testing in fixed drug eruptions. A 20-year review. Contact Dermatitis 65(4):195–201PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Barbaud A, Collet E, Milpied B, Assier H, Staumont D, Avenel-Audran M et al (2013) A multicenter study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions. Br J Dermatol 168(3):555–562PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Renn C, Straff W, Dorfmüller A, Al-Masaoudi T, Merk H, Sachs B (2002) Amoxicillin-induced rash in young adults with infectious mononucleosis: demonstration of drug specific reactivity. Br J Dermatol 147(6):1166–1170PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Coster A, Aerts O, Herman A, Marot L, Horst N, Kenyon C et al (2019) Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome caused by first-line antituberculous drugs: two case reports and a review of the literature. Contact Dermatitis 81:325PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Ohtoshi S, Kitami Y, Sueki H, Nakada T (2014) Utility of patch testing for patients with drug eruption. Clin Exp Dermatol 39(3):279–283PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Shiohara T, Mizukawa Y, Teraki Y (2002) Pathophysiology of fixed drug eruption: the role of skin-resident T cells. Curr Opin Allergy Clin Immunol 2(4):317–323PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Shiohara T, Mizukawa Y (2012) Fixed drug eruption: the dark side of activation of intraepidermal CD8+ T cells uniquely specialized to mediate protective immunity. Chem Immunol Allergy 97:106–121PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Alanko K (1994) Topical provocation of fixed drug eruption. A study of 30 patients. Contact Dermatitis 31:25–27PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Gonçalo M, Ferguson J, Bonevalle A, Bruynzeel DP, Giménez-Arnau A, Goossens A et al (2013) Photopatch testing: recommendations for a European photopatch test baseline series. Contact Dermatitis 68(4):239–243PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Fujimoto N, Danno K, Wakabayashi M, Uenishi T, Tanaka T (2009) Photosensitivity with eosinophilia due to ambroxol and UVB. Contact Dermatitis 60:110–113PubMedCrossRefPubMedCentralGoogle Scholar
  56. 56.
    Gonçalo M (1998) Explorations dans les photo-allergies médicamenteuses. In: GERDA (ed) Progrès en Dermato-allergologie. John Libbey Eurotext, Nancy, pp 67–74Google Scholar
  57. 57.
    Gonçalo M, Barros M, Azenha A, Bastos S, Figueiredo A (1996) The importance of photopatch testing in patients with photosensitive drug eruptions. JEADV 7:s20Google Scholar
  58. 58.
    Pinho A, Santiago L, Gonçalo M (2017) Patch testing in the investigation of non-immediate cutaneous adverse drug reactions to metamizole. Contact Dermatitis 76(4):238–239PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Batista M, Cardoso J, Oliveira P, Gonçalo M (2018) Allopurinol-induced DRESS syndrome presented as a cholecystitis-like acute abdomen and aggravated by antibiotics. BMJ Case RepGoogle Scholar
  60. 60.
    Brajon D, Menetre S, Waton J, Poreaux C, Barbaud A (2014) Non-irritant concentrations and amounts of active ingredient in drug patch tests. Contact Dermatitis 71(3):170–175PubMedCrossRefPubMedCentralGoogle Scholar
  61. 61.
    Assier H, Valeyrie-allanore L, Gener G, Carvalh MV, Chosidow O, Wolkenstein P (2017) Patch testing in non-immediate cutaneous adverse drug reactions: value of extemporaneous patch tests. Contact Dermatitis 77(5):297–302PubMedCrossRefPubMedCentralGoogle Scholar
  62. 62.
    Brockow K, Garvey LH, Aberer W, Atanaskovic-Markovic M, Barbaud A, Bilo MB et al (2013) Skin test concentrations for systemically administered drugs -an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy 68(6):702–712PubMedCrossRefPubMedCentralGoogle Scholar
  63. 63.
    Wolkenstein P, Chosidow O, Fléchet M-L, Robbiola O, Paul M, Dumé L et al (1996) Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Contact Dermatitis 35(4):234–236PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Mashiah J, Brenner S (2003) A systemic reaction to patch testing for the evaluation of acute generalized exanthematous pustulosis. Arch Dermatol 139:1181–1183PubMedCrossRefPubMedCentralGoogle Scholar
  65. 65.
    Barbaud A, Reichert-Penetrat S, Tréchot P, Jaqui-Petit M-A, Ehlinger A, Noirez V et al (1998) The use of skin testing in the investigation of cutaneous adverse drug reactions. Br J Dermatol 139:49–58PubMedCrossRefPubMedCentralGoogle Scholar
  66. 66.
    Vaillant L, Camenen I, Lorette G (1989) Patch testing with carbamazepine: reinduction of an exfoliative dermatitis. Arch Dermatol 125(2):299PubMedCrossRefPubMedCentralGoogle Scholar
  67. 67.
    Shebe K, Ngwanya MR, Gantsho N, Lehloenya RJ (2014) Severe recurrence of drug rash with eosinophilia and systemic symptoms syndrome secondary to rifampicin patch testing in a human immunodeficiency virus-infected man. Contact Dermatitis 70(2):125–127PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    Salman A, Yucelten D, Cakici O, Kadayifci E (2019) Acute generalized exanthematous pustulosis due to ceftriaxone: report of a pediatric case with recurrence after positive patch test. Pediatr Dermatol 36(4):514–516Google Scholar
  69. 69.
    Pietzcker F, Kuner V (1975) Anaphylaxie nach epicutanem ampicillin-test. Z Hautkr 50:437–440PubMedPubMedCentralGoogle Scholar
  70. 70.
    Jonker M, Bruynzeel D (2003) Anaphylactic reaction by patch testing with diclofenac. Contact Dermatitis 49:114–115PubMedCrossRefPubMedCentralGoogle Scholar
  71. 71.
    van Ketel W (1975) Patch testing in penicillin allergy. Contact Dermatitis 1(4):253–254PubMedCrossRefPubMedCentralGoogle Scholar
  72. 72.
    Romano A, Viola M, Gaeta F, Rumi G (2008) Patch testing in non-immediate drug eruptions. Allergy Asthma Clin Immunol 4(2):66–74PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Gonçalo M, Coutinho I, Teixeira V, Gameiro AR, Brites MM, Nunes R et al (2013) HLA-B∗58:01 is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome/toxic epidermal necrolysis in a Portuguese population. Br J Dermatol 169(3):660PubMedCrossRefPubMedCentralGoogle Scholar
  74. 74.
    Lammintausta K, KorteKangas-Savolainen O (2005) Oral challenge in suspected cutaneous adverse drug reactions. Acta Derm Venereol 85:491–496PubMedPubMedCentralGoogle Scholar
  75. 75.
    Romano A, Caubet J-C (2014) Antibiotic allergies in children and adults: from clinical symptoms to skin testing diagnosis. J Allergy Clin Immunol 2(1):3–12CrossRefGoogle Scholar
  76. 76.
    Bellini V, Pelliccia S, Lisi P (2013) Drug- and virus- or bacteria-induced exanthems: the role of immunohistochemical staining for cytokines in differential diagnosis. Dermatitis 24(2):85–90PubMedCrossRefPubMedCentralGoogle Scholar
  77. 77.
    Osawa J, Naito S, Aihara M, Kitamura K, Ikezawa Z, Nakajima H (1990) Evaluation of skin test reactions in patients with non-immediate type drug eruptions. J Dermatol 17:235–239PubMedCrossRefPubMedCentralGoogle Scholar
  78. 78.
    Hassoun-kheir N, Bergman R, Weltfriend S (2016) The use of patch tests in the diagnosis of delayed hypersensitivity drug eruptions. Int J Dermatol 55(11):1219–1224PubMedCrossRefPubMedCentralGoogle Scholar
  79. 79.
    Özkaya-Bayazit E, Bayazit H, Özmarmagan G (1999) Topical provocation in 27 cases of cotrimoxazole-induced fixed drug eruption. Contact Dermatitis 41(4):185–189PubMedCrossRefPubMedCentralGoogle Scholar
  80. 80.
    Romano A, Gaeta F, Valluzzi R, Alonzi C, Maggioletti M, Zaffiro A et al (2013) Absence of cross-reactivity to carbapenems in patients with delayed hypersensitivity to penicillins. Allergy 68(12):1618–1621PubMedCrossRefPubMedCentralGoogle Scholar
  81. 81.
    Barbaud A (2014) Skin testing and patch testing in non-IgE-mediated drug allergy. Curr Allergy Asthma Rep 14(6):442PubMedCrossRefPubMedCentralGoogle Scholar
  82. 82.
    Brinca A, Santiago F, Ramos L, Tellechea O, Gonçalo M (2012) Delayed hypersensitivity to low molecular weight heparin-what alternative to anticoagulation? Rev SPDV 70(1):117–122Google Scholar
  83. 83.
    Rive CM, Bourke J, Phillips EJ (2013) Testing for drug hypersensitivity syndromes. Clin Biochem Rev 34(1):15–38PubMedPubMedCentralGoogle Scholar
  84. 84.
    Lin Y-T, Chang Y-C, Hui RC-Y, Yang C-H, Ho H-C, Hung S-I et al (2012) A patch testing and cross-sensitivity study of carbamazepine-induced severe cutaneous adverse drug reactions. J Eur Acad Dermatol Venereol 3:356–364Google Scholar
  85. 85.
    Pirker C, Misic A, Brinkmeier T, Frosch P (2002) Tetrazepam drug sensitivity – usefulness of the patch test. Contact Dermatitis 47:135–138PubMedCrossRefPubMedCentralGoogle Scholar
  86. 86.
    Sousa-Basto A, Azenha A, Duarte M, Pardal-Oliveira F (1993) Generalized cutaneous reaction to diltiazem. Contact Dermatitis 29(1):44–45PubMedCrossRefPubMedCentralGoogle Scholar
  87. 87.
    Opstrup M, Guldager S, Zachariae C, Thyssen J (2017) Systemic allergic dermatitis caused by diltiazem. Contact Dermatitis 76(6):364–365PubMedCrossRefPubMedCentralGoogle Scholar
  88. 88.
    Santiago L, Moura AL, Coutinho I, Gonçalo M (2018) Systemic allergic contact dermatitis associated with topical diltiazem and/or cinchocaine. J Eur Acad Dermatol Venereol 32:e284PubMedCrossRefPubMedCentralGoogle Scholar
  89. 89.
    Barbaud A, Trechot P, Weber-Muller F, Ulrich G, Commun N, Schmutz JL (2004) Drug skin tests in cutaneous adverse drug reactions to pristinamycin: 29 cases with a study of cross-reactions between synergistins. Contact Dermatitis 50(1):22–26PubMedCrossRefPubMedCentralGoogle Scholar
  90. 90.
    Lombardo C, Bonadonna P (2015) Hypersensitivity reactions to proton pump inhibitors. Curr Treat Options Allergy 2:110–123CrossRefGoogle Scholar
  91. 91.
    Fernandes R, Regateiro FS, Faria E, Martinho A, Gonçalo M, Todo-bom A (2018) Drug reaction with eosinophilia and systemic symptoms caused by spironolactone: case report. Contact Dermatitis 79:255–256PubMedCrossRefPubMedCentralGoogle Scholar
  92. 92.
    Romano A, Blanca M, Torres MJ, Bircher A, Aberer W, Brockow K et al (2004) Diagnosis of nonimmediate reactions to beta-lactam antibiotics. Allergy 59(11):1153–1160PubMedCrossRefPubMedCentralGoogle Scholar
  93. 93.
    Romano A, Gaeta F, Valluzzi RL, Caruso C, Alonzi C, Viola M et al (2012) Diagnosing nonimmediate reactions to cephalosporins. J Allergy Clin Immunol 129(4):1–9CrossRefGoogle Scholar
  94. 94.
    Pinho A, Coutinho I, Gameiro A, Gouveia M, Gonçalo M (2017) Patch testing – a valuable tool for investigating non-immediate cutaneous adverse drug reactions to antibiotics. J Eur Acad Dermatol Venereol 31(2):280–287PubMedCrossRefPubMedCentralGoogle Scholar
  95. 95.
    Romano A, Gaeta F, Poves MA, Valluzzi R (2016) Cross-reactivity among Beta-Lactams. Curr Allergy Asthma Rep 16:24PubMedCrossRefPubMedCentralGoogle Scholar
  96. 96.
    Nicholson P, Brinsley J, Farooque S, Wakelin S (2018) Patch testing with meropenem following a severe cutaneous adverse drug reaction. Contact Dermatitis 79(6):397–398PubMedCrossRefPubMedCentralGoogle Scholar
  97. 97.
    Pereira N, Canelas MM, Santiago F, Brites MM, Gonçalo M (2011) Value of patch tests in clindamycin-related drug eruptions. Contact Dermatitis 65(4):202–207PubMedCrossRefPubMedCentralGoogle Scholar
  98. 98.
    Seitz C, Bröcker E, Trautmann A (2009) Allergy diagnostic testing in clindamycin-induced skin reactions. Int Arch Allergy Immunol 149(3):246–250PubMedCrossRefPubMedCentralGoogle Scholar
  99. 99.
    Schmid DA, Depta JPH, Pichler WJ (2006) T cell-mediated hypersensitivity to quinolones: mechanisms and cross-reactivity. Clin Exp Allergy 36(1):59–69PubMedCrossRefPubMedCentralGoogle Scholar
  100. 100.
    Brockow K (2005) Contrast media hypersensitivity – scope of the problem. Toxicology 206:189–192CrossRefGoogle Scholar
  101. 101.
    Gonçalo M, Oliveira HSH, Fernandes B, Robalo-Cordeiro M, Figueiredo A (2002) Topical provocation in fixed drug eruption from nonsteroidal anti-inflammatory drugs. Exog Dermatol 1(2):81–86CrossRefGoogle Scholar
  102. 102.
    Blanca M, Romano A, Torres M, Férnandez J, Mayorga C, Rodriguez J et al (2009) Update on the evaluation of hypersensitivity reactions to betalactams. Allergy 64(2):183–193PubMedCrossRefPubMedCentralGoogle Scholar
  103. 103.
    Phillips E, Sullivan J, Knowles S, Shear N (2002) Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir. AIDS 16:2223–2225PubMedCrossRefPubMedCentralGoogle Scholar
  104. 104.
    Phillips E, Mallal S (2009) Successful translation of pharmacogenetics into the clinic: the abacavir example. Mol Diagn Ther 13:1–9PubMedCrossRefPubMedCentralGoogle Scholar
  105. 105.
    Elzagallaai A, Knowles S, Rieder M, Brend J, Shear N, Koren G (2009) Patch testing in the diagnosis of anticonvulsant hypersensitivity syndrome. A systematic review. Drug Saf 32:391–408PubMedCrossRefPubMedCentralGoogle Scholar
  106. 106.
    Ben Fredj N, Aouam K, Chaabane A, Toumi A, Ben Rhomdhane F, Boughattas N et al (2010) Hypersensitivity to amoxicillin after drug rash with eosinophilia and systemic symptoms (DRESS) to carbamazepine and allopurinol: a possible co-sensitization. Br J Clin Pharmacol 70(2):273–276PubMedCrossRefPubMedCentralGoogle Scholar
  107. 107.
    Lee A (1998) Topical provocation in 31 cases of fixed drug eruption: change of causative drugs in 10 years. Contact Dermatitis 38:258–260PubMedCrossRefPubMedCentralGoogle Scholar
  108. 108.
    Oliveira HS, Gonçalo M, Reis JP, Figueiredo A (1999) Fixed drug eruption to piroxicam. Positive patch tests with cross-sensitivity to tenoxicam. J Dermatolog Treat 10(3):209–212CrossRefGoogle Scholar
  109. 109.
    Robalo-Cordeiro M, Gonçalo M, Fernandes B, Oliveira H, Figueiredo A (2000) Positive lesional patch tests in fixed drug eruptions from nimesulide. Contact Dermatitis 43:307Google Scholar
  110. 110.
    Andrade P, Gonçalo M (2011) Fixed drug eruption caused by etoricoxib-2 cases confirmed by patch testing. Contact Dermatitis 64(2):118–120PubMedCrossRefPubMedCentralGoogle Scholar
  111. 111.
    Gonçalo M, Giménez-Arnau A (2015) Drug photosensitivity. In: Katsambas AD, Lotti TM, Dessinioti C, D’Erme AM (eds) European handbook of dermatological treatments, 3rd edn. Springer, Berlin/Heidelberg, pp 233–251CrossRefGoogle Scholar
  112. 112.
    Cardoso JC, Canelas MM, Gonçalo M, Figueiredo A (2009) Photopatch testing with an extended series of photoallergens: a 5-year study. Contact Dermatitis 60(6):325–329PubMedCrossRefPubMedCentralGoogle Scholar
  113. 113.
    Gonçalo M, Figueiredo A, Tavares P, Fontes Ribeiro C, Teixeira F, Poiares Baptista A (1992) Photosensitivity to piroxicam: absence of cross reaction with tenoxicam. Contact Dermatitis 27:287–290PubMedCrossRefPubMedCentralGoogle Scholar
  114. 114.
    Varela P, Amorim I, Massa A, Sanches M, Silva E (1998) Piroxicam-beta-cyclodextrin and photosensitivity reactions. Contact Dermatitis 38(4):229PubMedCrossRefPubMedCentralGoogle Scholar
  115. 115.
    Serra D, Gonçalo M, Figueiredo A (2008) Two decades of cutaneous adverse drug reactions from piroxicam. Contact Dermatitis 58(S1):35Google Scholar
  116. 116.
    Rato M, Gil F, Monteiro AF, Parente J (2018) Fenofibrate photoallergy – relevance of patch and photopatch testing. Contact Dermatitis 78(6):413–414PubMedCrossRefPubMedCentralGoogle Scholar
  117. 117.
    Kuwatsuka S, Kuwatsuka Y, Takenaka M, Utani A (2016) Case of photosensitivity caused by fenofibrate after photosensitization to ketoprofen. J Dermatol 43(2):224–225PubMedCrossRefPubMedCentralGoogle Scholar
  118. 118.
    Tsai K, Yang J, Hung S (2017) Fenofibrate-induced photosensitivity – a case series and literature review. Photodermatol Photoimmunol Photomed 33:213–219PubMedCrossRefPubMedCentralGoogle Scholar
  119. 119.
    Oliveira HS, Gonçalo M, Figueiredo AC (2000) Photosensitivity to lomefloxacin. A clinical and photobiological study. Photodermatol Photoimmunol Photomed 16(3):116PubMedCrossRefPubMedCentralGoogle Scholar
  120. 120.
    Kimura M, Kawada A (1998) Photosensitivity induced by lomefloxacin with cross-photosensitivity to ciprofloxacin and fleroxacin. Contact Dermatitis 38(3):180PubMedCrossRefPubMedCentralGoogle Scholar
  121. 121.
    Kurumajin Y, Shono M (1992) Scarified photopatch testing in lomefloxacin photosensitivity. Contact Dermatitis 26:5–10CrossRefGoogle Scholar
  122. 122.
    Gómez-Bernal S, Álvarez-Pérez A, Rodríguez-Pazos L, Gutiérrez-González E, Rodríguez-Granados MT, Toribio J (2014) Fotosensibilidad por tiazidas. Actas Dermosifiliogr 105(4):359–366PubMedCrossRefPubMedCentralGoogle Scholar
  123. 123.
    Gonçalo M, Domingues J, Correia O, Figueiredo A (1999) Fotossensibilidad a flutamida. Bol Inf GEIDC 29:45–48Google Scholar
  124. 124.
    Martín-Lázaro J, Buján J, Arrondo A, Galindo E, Capdevilla E (2004) Is photopatch testing useful in the investigation of photosensitivity due to flutamide? Contact Dermatitis 50:325–326PubMedCrossRefPubMedCentralGoogle Scholar
  125. 125.
    Gutiérrez-gonzález E, Rodríguez-pazos L, Rodríguez-granados MT, Toribio J (2011) Photosensitivity induced by naproxen. Photodermatol Photoimmunol Photomed. 27:338–340PubMedCrossRefPubMedCentralGoogle Scholar
  126. 126.
    Yoshimoto E, Konishi M, Takahashi K, Murukawa K, Maeda K, Mikasa K et al (2004) The first case of efavirenz-induced photosensitivity in a Japanese patient with HIV infection. Intern Med 43:630–631PubMedCrossRefPubMedCentralGoogle Scholar
  127. 127.
    Verma R, Vasudevan B, Shankar S, Pragasam V, Suwal B, Venugopal R (2012) First reported case of tenofovir-induced photoallergic reaction. Indian J Pharmacol 44(5):651–653PubMedPubMedCentralCrossRefGoogle Scholar
  128. 128.
    Park M, Shim W, Kim J, Kim G, Kim H, Ko H et al (2017) Pirfenidone-induced photo-allergic reaction in a patient with idiopathic pulmonary fibrosis. Photodermatol Photoimmunol Photomed 33:209–212PubMedCrossRefPubMedCentralGoogle Scholar
  129. 129.
    Romita P, Foti C, Stingeni L (2017) Photoallergy to promazine hydrochloride. Contact Dermatitis 77(3):182–183PubMedCrossRefPubMedCentralGoogle Scholar
  130. 130.
    Lee A, Joo H, Chey W, Kim Y (2001) Photopatch testing in seven cases of photosensitive drug eruptions. Ann Pharmacother 35:1584–1587PubMedCrossRefPubMedCentralGoogle Scholar
  131. 131.
    Romano A, Guéant-Rodriguez R-M, Viola M, Gaeta F, Caruso C, Guéant J-L (2005) Cross-reactivity among drugs: clinical problems. Toxicology 209(2):169–179PubMedCrossRefPubMedCentralGoogle Scholar
  132. 132.
    Romano A, Gaeta F, Valluzzi L, Maggioletti M (2016) Cross-reactivity and tolerability of aztreonam and cephalosporins in subjects with a T cell – mediated hypersensitivity to penicillins. J Allergy Clin Immunol 138(1):179–186PubMedCrossRefPubMedCentralGoogle Scholar
  133. 133.
    Romano A, Valluzzi RL, Caruso C, Maggioletti M, Quarantino D, Gaeta F (2018) Cross-reactivity and tolerability of cephalosporins in patients with IgE-mediated hypersensitivity to penicillins. J Allergy Clin Immunol Pract 6(5):1662–1672PubMedCrossRefPubMedCentralGoogle Scholar
  134. 134.
    Romano A, Pettinato R, Andriolo M, Viola M, Guéant-Rodriguez R, Valluzzi R et al (2006) Hypersensitivity to aromatic anticonvulsants: in vivo and in vitro cross-reactivity studies. Curr Pharm Des 12(26):3373–3381PubMedCrossRefPubMedCentralGoogle Scholar
  135. 135.
    Barbaud A, Girault P-Y, Schmutz J-L, Weber-Muller F, Trechot P (2009) No cross-reactions between tetrazepam and other benzodiazepines: a possible chemical explanation. Contact Dermatitis 61:53–56PubMedCrossRefPubMedCentralGoogle Scholar
  136. 136.
    Vander Hulst K, Kerre S, Goossens A (2010) Occupational allergic contact dermatitis from tetrazepam in nurses. Contact Dermatitis 62(5):303–308PubMedCrossRefPubMedCentralGoogle Scholar
  137. 137.
    Cravo M, Gonçalo M, Figueiredo A (2007) Fixed drug eruption to cetirizine with positive lesional patch tests to the three piperazine derivatives. Int J Dermatol 46(7):760–762PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Clinic of Dermatology, University Hospital and Faculty of MedicineUniversity of CoimbraCoimbraPortugal
  2. 2.AbcoudeThe Netherlands

Personalised recommendations